About Us
We are developing potentially best in class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
About the Role
| Role | Location | Salary | Posted |
|---|---|---|---|
| Director/Senior Director, Project ManagementDianthustherapeutics · Remote | Remote | — | 2026-07-22 |
| Director, Biologics Formulation DevelopmentDianthustherapeutics · Remote | Remote | — | 2026-07-22 |
| Manager, Supply Chain LogisticsDianthustherapeutics · Remote | Remote | — | 2026-07-22 |
| System Administrator, Identity & Access ManagementDianthustherapeutics · Remote | Remote | — | 2026-07-22 |
| Associate Director, Clinical OperationsDianthustherapeutics · Remote | Remote | — | 2026-07-22 |
| Associate Director/Director Drug Product, CMCDianthustherapeutics · Remote | Remote | — | 2026-07-22 |